Tenax Therapeutics (TENX) – Analysts’ Weekly Ratings Changes

Tenax Therapeutics (NASDAQ: TENX) recently received a number of ratings updates from brokerages and research firms:

• 8/15/2026 – Tenax Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/11/2026 – Tenax Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Guggenheim. They now have a “buy” rating on the stock.
• 8/11/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $4.00 price target on the stock, down from $40.00.
• 8/11/2026 – Tenax Therapeutics was given a new $4.00 price target by Leerink Partners.
• 8/11/2026 – Tenax Therapeutics was downgraded by Chardan Capital from “buy” to “neutral”. They now have a $5.00 price target on the stock.
• 8/11/2026 – Tenax Therapeutics was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $5.00 price target on the stock.
• 8/10/2026 – Tenax Therapeutics was downgraded by William Blair from “outperform” to “market perform”.
• 8/10/2026 – Tenax Therapeutics was given a new $5.00 price target by Roth Capital.
• 7/31/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $27.00 price target on the stock.
• 7/29/2026 – Tenax Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $35.00 price target on the stock.
• 7/28/2026 – Tenax Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $35.00 price target on the stock.
• 7/22/2026 – Tenax Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $39.00 price target on the stock.
• 7/2/2026 – Tenax Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $27.00 price target on the stock.
• 6/30/2026 – Tenax Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Tenax Therapeutics

In other Tenax Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 716,369 shares of the stock in a transaction dated Friday, August 21st. The shares were bought at an average price of $1.77 per share, with a total value of $1,267,973.13. Following the purchase, the insider directly owned 4,746,444 shares of the company’s stock, valued at approximately $8,401,205.88. This trade represents a 17.78% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have bought 1,025,867 shares of company stock worth $1,815,658. Company insiders own 10.81% of the company’s stock.

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.